Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $15.71 Consensus Target Price from Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY) has received a consensus rating of “Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $15.71.

Several research analysts recently weighed in on INZY shares. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Jefferies Financial Group reissued a “buy” rating and set a $17.00 price target (up from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Stifel Nicolaus initiated coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and issued a $12.00 price target (down from $15.00) on shares of Inozyme Pharma in a report on Tuesday, November 5th.

Inozyme Pharma Stock Performance

Shares of Inozyme Pharma stock opened at $2.64 on Thursday. Inozyme Pharma has a 52 week low of $2.61 and a 52 week high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The stock has a market capitalization of $169.59 million, a price-to-earnings ratio of -1.80 and a beta of 1.54. The firm has a fifty day moving average of $4.66 and a two-hundred day moving average of $4.83.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. As a group, equities research analysts predict that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Investors Weigh In On Inozyme Pharma

Several institutional investors have recently bought and sold shares of the company. Millennium Management LLC raised its holdings in shares of Inozyme Pharma by 154.1% in the second quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock valued at $7,974,000 after purchasing an additional 1,084,341 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in Inozyme Pharma by 40.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock valued at $20,242,000 after buying an additional 756,717 shares during the last quarter. Samlyn Capital LLC lifted its position in Inozyme Pharma by 15.0% during the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after buying an additional 437,622 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Inozyme Pharma by 117.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock worth $1,695,000 after buying an additional 205,417 shares during the last quarter. Finally, Eventide Asset Management LLC grew its holdings in shares of Inozyme Pharma by 5.0% in the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after acquiring an additional 198,216 shares in the last quarter. Institutional investors own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.